THE WOODLANDS, Texas,
July 24, 2017 /PRNewswire/
-- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release
its second quarter 2017 financial results on Tuesday, August 1, 2017 before market opens.
Management will conduct a conference call and live webcast at
8:00 a.m. EDT (7:00 a.m. CDT) that day to discuss the financial
results and to provide a business update.
Dial-in Information
U.S. Dial-in Number: (888)
645-5785
International Dial-in Number: (970) 300-1531
Conference ID: 8318300
Replay Information
U.S. Dial-in Number: (855)
859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 8318300
The dial-in replay will be available for 7 days following the
call. An audio webcast will be available online in the investor
relations section of the company website at
www.lexpharma.com/investors, with a webcast replay accessible for
14 days after the call.
About Lexicon Pharmaceuticals
Lexicon is a fully
integrated biopharmaceutical company that is applying a unique
approach to gene science based on Nobel Prize-winning technology to
discover and develop precise medicines for patients with serious,
chronic conditions. Through its Genome5000™ program, Lexicon
scientists have studied the role and function of nearly 5,000 genes
over the last 20 years and have identified more than 100 protein
targets with significant therapeutic potential in a range of
diseases. Through the precise targeting of these proteins, Lexicon
is pioneering the discovery and development of innovative medicines
to safely and effectively treat disease. In addition to its first
commercial product, XERMELO® (telotristat ethyl)
for carcinoid syndrome diarrhea, Lexicon has a pipeline of
promising drug candidates in clinical and pre-clinical development
in diabetes and metabolism and neuropathic pain. For additional
information please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains
"forward-looking statements," including statements relating to
Lexicon's commercialization of XERMELO (telotristat ethyl) 250 mg
and clinical development of sotagliflozin, LX2761 and LX9211. In
addition, this press release also contains forward looking
statements relating to Lexicon's growth and future operating
results, discovery and development of products, strategic alliances
and intellectual property, as well as other matters that are not
historical facts or information. All forward-looking statements are
based on management's current assumptions and expectations and
involve risks, uncertainties and other important factors,
specifically including the degree of market acceptance of XERMELO,
the availability of coverage and reimbursement for XERMELO,
Lexicon's dependence on third parties for manufacturing and
distribution of XERMELO, Lexicon's compliance with applicable legal
and regulatory requirements and other factors relating to the
commercialization of XERMELO. Other risks include Lexicon's ability
to meet its capital requirements, successfully conduct preclinical
and clinical development and obtain necessary regulatory approvals
of sotagliflozin, LX2761, LX9211 and its other potential drug
candidates, achieve its operational objectives, obtain patent
protection for its discoveries and establish strategic alliances,
as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial
value of its drug candidates. Any of these risks, uncertainties and
other factors may cause Lexicon's actual results to be materially
different from any future results expressed or implied by such
forward-looking statements. Information identifying such
important factors is contained under "Risk Factors" in Lexicon's
annual report on Form 10-K for the year ended December 31, 2016, as filed with the Securities
and Exchange Commission. Lexicon undertakes no obligation to update
or revise any such forward-looking statements, whether as a result
of new information, future events or otherwise.
View original
content:http://www.prnewswire.com/news-releases/lexicon-pharmaceuticals-to-host-second-quarter-2017-financial-results-conference-call-and-webcast-on-august-1-2017-300492741.html
SOURCE Lexicon Pharmaceuticals, Inc.